• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
PVP-K30-----pharma excipients(CAS No.9003-39-8)
Tobramycin
Povidone iodine 20% powder
Povidone iodine 10% powder
SULBACTAM SODIUM STERILE
Food Additives Bulk Sucralose Neotame Advantame Powder

U.S. to send 500,000 Pfizer COVID-19 vaccine doses to Uruguay

firstwordpharmaJuly 09, 2021

Tag: Pfizer , COVID-19 , Vaccine

The United States will send 500,000 doses of Pfizer’s COVID-19 vaccine to Uruguay on Thursday, the White House said, as reported by the National Post.

U.S. to send 500,000 Pfizer COVID-19 vaccine doses to Uruguay

Meanwhile, the White House on Wednesday said the US would send 1 million Johnson & Johnson COVID-19 vaccine doses to Bolivia and 1 million to Paraguay.


Previous:Cyclerion Therapeutics and Beacon Biosignals Announce Expanded Strategic Partnership

Next:Pfizer plans to seek FDA nod for COVID-19 booster next month as Delta spreads

Related News

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China

PharmaSourcesSeptember 19, 2024

InnoCare Pharma announced today the approval of the Investigational New Drug (IND) to conduct the clinical trial of B-cell lymphoma-2 (BCL2) inhibitor ICP-248 in combination with azacitidine for acute myeloid leukemia (AML) in China.

Cordlife Unveils Enhanced Processing and Storage Facility in Singapore; Strengthens Processes as It Resumes Collection of Cord Blood Units in a Controlled Manner

PharmaSourcesSeptember 18, 2024

Latest Data of InnoCare’s Orelabrutinib Presented at the European Society for Medical Oncology (ESMO) Congress 2024

PharmaSourcesSeptember 14, 2024

U.S. to send 500,000 Pfizer COVID-19 vaccine doses to Uruguay | Pharmasources.com

Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study

Biotech NewswireAugust 28, 2024

Currax Pharmaceuticals LLC announced the results of a Cardiovascular Health Outcomes Analysis.The results showed there is no evidence of excess cardiovascular risk.

You may like
More>>

Influenza Vaccine in 2022-2023

Influenza Vaccine in 2022-2023
Hualan bio H7N9 Inactivated Influenza Vaccine by Hualan Bio

Hualan bio H7N9 Inactivated Influenza Vaccine by Hualan Bio
High-quality Influenza Vaccine (Split virion), inactivated

High-quality Influenza Vaccine (Split virion), inactivated
Hepatitis A (Live) Vaccine, Freeze-Dried

Hepatitis A (Live) Vaccine, Freeze-Dried
Human Vaccine

Human Vaccine
Automatic GMP Washing and Drying System Meet Requirement of Pharmaceutical and Vaccine Production

Automatic GMP Washing and Drying System Meet Requirement of Pharmaceutical and Vaccine Production
Influenza Vaccine(Split Virion),Inactivated

Influenza Vaccine(Split Virion),Inactivated
Influenza A (H1N1) Vaccine, (Split, Inactivated)by Hualan biological 1

Influenza A (H1N1) Vaccine, (Split, Inactivated)by Hualan biological 1
Trivalent Vaccine

Trivalent Vaccine
Hualan Bio-H7N9 Inactivated Influenza Vaccine

Hualan Bio-H7N9 Inactivated Influenza Vaccine

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service